Download MendeleyDiscovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors.
DeRatt, L.G., Pietsch, E.C., Cisar, J.S., Jacoby, E., Kazmi, F., Matico, R., Shaffer, P., Tanner, A., Wang, W., Attar, R., Edwards, J.P., Kuduk, S.D.(2024) ACS Med Chem Lett 15: 381-387
- PubMed: 38505861
- DOI: https://doi.org/10.1021/acsmedchemlett.3c00543
- Primary Citation of Related Structures:
8VHL, 8VHM - PubMed Abstract:
Dihydroorotate dehydrogenase (DHODH) is a mitochondrial enzyme that affects many aspects essential to cell proliferation and survival. Recently, DHODH has been identified as a potential target for acute myeloid leukemia therapy. Herein, we describe the identification of potent DHODH inhibitors through a scaffold hopping approach emanating from a fragment screen followed by structure-based drug design to further improve the overall profile and reveal an unexpected novel binding mode. Additionally, these compounds had low P-gp efflux ratios, allowing for applications where exposure to the brain would be required.
Organizational Affiliation:
Janssen Pharmaceutical Research and Development, 1400 McKean Rd., Spring House, Pennsylvania 19477, United States.
